J C Nolan
Overview
Explore the profile of J C Nolan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nolan J, Frawley T, Tighe J, Soh H, Curtin C, Piskareva O
Cancer Lett
. 2020 Jan;
474:53-62.
PMID: 31962141
Neuroblastoma is a paediatric cancer of the sympathetic nervous system and the most common solid tumour of infancy, contributing to 15% of paediatric oncology deaths. Current therapies are not effective...
2.
Curtin C, Nolan J, Conlon R, Deneweth L, Gallagher C, Tan Y, et al.
Acta Biomater
. 2018 Feb;
70:84-97.
PMID: 29447961
Statement Of Significance: Traditional 2D cell cultures do not completely capture the 3D architecture of cells and extracellular matrix contributing to a gap in our understanding of mammalian biology at...
3.
Watts N, Nolan J, Brennan J, Yang H
Menopause
. 2000 Dec;
7(6):375-82.
PMID: 11127759
Objective: To determine the relationships among bone mineral density changes, bone marker changes, and plasma estrogens in postmenopausal women receiving estrogen replacement therapy. Design: A total of 406 postmenopausal women...
4.
Genant H, Lucas J, Weiss S, Akin M, Emkey R, Downs R, et al.
Arch Intern Med
. 1998 Apr;
157(22):2609-15.
PMID: 9531230
Background: Prospective studies have shown that doses equivalent to conjugated equine estrogens of 0.625 mg/d or higher are needed to produce a significant increase in bone mineral density of the...
5.
Cefali E, Nolan J, McConnell W, Walters D
Pharm Res
. 1995 Feb;
12(2):270-4.
PMID: 7784344
Zeolite A is a synthetic zeolite which may have therapeutic utility in osteoporotic individuals because of its ability to stimulate bone formation. A study of Zeolite A (30 mg/kg), sodium...
6.
Kerwar S, Ridge S, LANDES M, Nolan J, Oronsky A
Agents Actions
. 1994 Dec;
43(3-4):206-9; discussion 210.
PMID: 7725974
No abstract available.
7.
Lo Y, Nolan J, MAREN T, Welstead Jr W, Gripshover D, Shamblee D
J Med Chem
. 1993 Jan;
35(26):4790-4.
PMID: 1479580
Several imidazolylphenyl sulfamate and (imidazolylphenoxy)alkyl sulfamate derivatives were synthesized and evaluated as topically active carbonic anhydrase inhibitors. Water solubility, pKa, carbonic anhydrase inhibition, and partition coefficient for the compounds were...
8.
Nolan J, Gathright C, Radvany C, Barrett R, SANCILIO L
Pharmacol Res
. 1991 Dec;
24(4):377-83.
PMID: 1805191
Adjuvant-induced arthritis in rats was attenuated by the therapeutic administration of carbonic anhydrase inhibitors. Female Lewis rats with established disease were treated daily (day 18 through day 50) with various...
9.
Sleevi M, CALE Jr A, Gero T, Jaques L, Welstead W, Johnson A, et al.
J Med Chem
. 1991 Apr;
34(4):1314-28.
PMID: 1673158
The enantiomers of 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4- oxazapine-5(2H)-thione (rocastine) and two of its more potent analogues were prepared with an enantiomeric purity of greater than 99.9%. The antihistaminic activity of these compounds was...
10.
Barrett R, Appell K, Kilpatrick B, Proakis A, Nolan J, Walsh D
J Cardiovasc Pharmacol
. 1991 Jan;
17(1):41-53.
PMID: 1708055
In vivo and in vitro methods were used to characterize AHR-16303B, a novel compound with antagonistic action at 5-HT2 receptors and voltage-sensitive calcium channels. The 5-HT2 receptor-antagonistic properties of AHR-16303B...